Table. Characteristics of 3 patients with PML who received nivolumab, France, 2017*.

Patient characteristics	Total lymphocytes; CD4+; CD8+, n/mm3	Clinical course	Additional therapy	JCV in CSF, log10 copies/mL	Loss of kidney function
Patient 1: age 81 y; received transplant 5 y before PML diagnosis; received treatment with Tac, MPA, prednisone	B: 300; 76; 56/LFU: 1,000; 602; 250†	Rapid progression of neurologic disorders despite 2 injections of nivolumab; death from progression of PML 6 wk after diagnosis	Mirtazapine 15 mg/d	B: 3.5/LFU: NA	No
Patient 2: age 77 y; received transplant 2 y before PML diagnosis; received treatment with belatacept, MPA, and prednisone	B: 377; 162; 106/LFU: 444; 117; 210‡	Rapid progression of neurologic disorders despite 3 injections of nivolumab; death from progression of PML 6 wk after diagnosis	Mirtazapine 15 mg/d; γ interferon therapy (100 μg) added 1 day after second and third injections	B: 2.9/LFU: 5	Yes
Patient 3: age 67 y; received transplant 17 y before PML diagnosis; received treatment with Tac, MPA, prednisone	B: 487; 287; 67/LFU: 2,076; 1,183; 477§	Rapid neurologic degradation despite 2 injections of nivolumab; death from progression of PML 4 wk after diagnosis	Mirtazapine 15 mg/d	B: 2.9/LFU: NA	No

*B, baseline; CSF, cerebrospinal fluid; JCV, JC virus; LFU, last follow-up; MPA, mycophenolic acid; NA, not available, PML, progressive multifocal leukoencephalopathy; Tac, tacrolimus.
†LFU for patient 1 was 1 wk after the second injection of nivolumab.
‡LFU for patient 2 was 4 d after the third injection of nivolumab.
§LFU for patient 3 was 1 wk after the second injection of nivolumab.